DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
AZD-5363 is an investigational drug.
There have been 30 clinical trials for AZD-5363. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2015.
The most common disease conditions in clinical trials are Lung Neoplasms, Adenocarcinoma, and Ovarian Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.
Recent Clinical Trials for AZD-5363
|Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||National Cancer Institute (NCI)||Phase 2|
|Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||M.D. Anderson Cancer Center||Phase 2|
|Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer||AstraZeneca||Phase 2|